Veracyte. has filed a patent for methods to classify and evaluate the prognosis of breast cancer patients. The invention involves using a supervised algorithm to predict breast cancer subtype based on gene expression profiles. The methods can guide treatment options and predict outcomes or response to therapy. The patent also includes means for evaluating gene expression profiles and kits for practicing the methods. GlobalData’s report on Veracyte gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Veracyte, ML-based biomarker screening was a key innovation area identified from patents. Veracyte's grant share as of September 2023 was 26%. Grant share is based on the ratio of number of grants to total number of patents.
Methods for classifying and evaluating prognosis of breast cancer
A recently filed patent (Publication Number: US20230272476A1) describes a method for determining the risk of recurrence (ROR) in individuals with breast cancer. The method involves measuring the RNA expression of 46 genes in the tumor and calculating a risk of recurrence score using a specific equation. The risk of recurrence score is an integer value on a 0-100 scale and is based on the correlation values of the tumor with four intrinsic subtypes of breast cancer. The method can help determine whether a subject has a low or high risk of recurrence based on the risk of recurrence score and interpretation of the score using risk classification and nodal status.
The patent also mentions that the risk being assessed can be breast cancer specific survival, event-free survival, or response to therapy. This suggests that the method can provide valuable information about the likelihood of survival and response to treatment in individuals with breast cancer.
Furthermore, the patent describes the use of the nanoreporter code system (nCounter® Analysis system) to determine the RNA expression of the genes in the NANO46 intrinsic gene list. This system allows for accurate and efficient measurement of gene expression levels.
Overall, this patent presents a method for determining the risk of recurrence in individuals with breast cancer based on the RNA expression of specific genes. The method has the potential to provide valuable information about the prognosis and treatment response in breast cancer patients. The use of the nanoreporter code system ensures accurate measurement of gene expression levels. Further research and validation are needed to assess the effectiveness and reliability of this method in clinical practice.
To know more about GlobalData’s detailed insights on Veracyte, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
